TXG
10x Genomics, Inc.
Stock
$93.50+4.74 (+5.34%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $617M | $643M | $611M | $619M | $516M | $490M | $299M | $246M | $146M | $71M |
| Cost of revenue | $185M | $199M | $196M | $209M | $120M | $74M | $58M | $61M | $29M | $11M |
| Gross profit | $432M | $444M | $414M | $409M | $396M | $416M | $240M | $185M | $118M | $61M |
| R&D | $227M | $239M | $265M | $270M | $266M | $212M | $123M | $83M | $48M | $32M |
| SG&A | $297M | $316M | $344M | $343M | $298M | $258M | $202M | $131M | $88M | $47M |
| Other operating expenses | — | — | — | $61M | — | — | $449M | $1.5M | $93M | — |
| Operating income | −$88M | −$61M | −$195M | −$265M | −$168M | −$52M | −$534M | −$31M | −$111M | −$18M |
| Non-operating income | $13M | $21M | $17M | $17M | $6.0M | −$1.5M | −$334K | −$460K | −$1.6M | −$366K |
| Pretax income | −$75M | −$40M | −$178M | −$249M | −$162M | −$54M | −$534M | −$31M | −$112M | −$19M |
| Taxes | $235K | $3.6M | $4.9M | $6.3M | $4.0M | $4.5M | $8.3M | $218K | $87K | $21K |
| Net income | −$75M | −$44M | −$183M | −$255M | −$166M | −$58M | −$543M | −$31M | −$112M | −$19M |
| Diluted EPS | −$0.59 | −$0.35 | −$1.52 | −$2.18 | −$1.46 | −$0.53 | −$5.37 | −$0.80 | −$8.40 | −$1.62 |
| Diluted shares | — | 124.7M | 120.5M | 117.2M | 113.9M | 110.3M | 101.2M | 39.1M | 13.4M | 11.6M |
| Revenue growth | — | +5.2% | −1.3% | +19.8% | +5.3% | +64.1% | +21.5% | +68.1% | +105.8% | — |
| Gross margin | 70.0% | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% | 80.4% | 75.2% | 80.4% | 85.1% |
| Operating margin | −14.3% | −9.5% | −31.9% | −42.9% | −32.5% | −10.7% | −178.7% | −12.4% | −75.7% | −25.8% |
| Net margin | −12.2% | −6.8% | −29.9% | −41.2% | −32.1% | −11.9% | −181.6% | −12.7% | −76.9% | −26.4% |